Your browser is no longer supported. Please, upgrade your browser.
AzurRx BioPharma, Inc.
Index- P/E- EPS (ttm)-0.88 Insider Own11.09% Shs Outstand49.44M Perf Week-3.98%
Market Cap87.66M Forward P/E- EPS next Y-0.43 Insider Trans0.00% Shs Float29.48M Perf Month-22.12%
Income-24.70M PEG- EPS next Q-0.14 Inst Own5.00% Short Float7.71% Perf Quarter118.06%
Sales- P/S- EPS this Y22.80% Inst Trans17.70% Short Ratio0.29 Perf Half Y109.65%
Book/sh0.49 P/B3.45 EPS next Y50.60% ROA-243.00% Target Price- Perf Year101.12%
Cash/sh0.22 P/C7.69 EPS next 5Y- ROE-472.30% 52W Range0.37 - 2.63 Perf YTD74.23%
Dividend- P/FCF- EPS past 5Y-22.50% ROI- 52W High-35.74% Beta1.72
Dividend %- Quick Ratio4.40 Sales past 5Y- Gross Margin- 52W Low355.69% ATR0.26
Employees10 Current Ratio4.40 Sales Q/Q- Oper. Margin- RSI (14)55.41 Volatility11.81% 14.37%
OptionableNo Debt/Eq0.00 EPS Q/Q-181.20% Profit Margin- Rel Volume0.32 Prev Close1.48
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume7.82M Price1.69
Recom2.20 SMA201.78% SMA5038.07% SMA20079.95% Volume2,477,110 Change14.19%
Jan-06-21Downgrade Dawson James Buy → Neutral
Jun-11-19Initiated National Securities Buy $9
Oct-17-18Initiated Oppenheimer Outperform $6
Jul-24-17Initiated H.C. Wainwright Buy $8
Feb-24-21 07:00AM  
Feb-16-21 07:00AM  
Feb-09-21 06:30AM  
Feb-08-21 08:00AM  
Jan-28-21 07:00AM  
Jan-26-21 07:00AM  
Jan-22-21 10:18AM  
Jan-21-21 10:34AM  
Jan-12-21 08:30AM  
Jan-08-21 09:00AM  
Jan-07-21 08:00AM  
Jan-06-21 08:00AM  
Jan-05-21 08:00AM  
Jan-04-21 07:00AM  
Nov-30-20 08:00AM  
Nov-24-20 08:17AM  
Nov-17-20 08:00AM  
Nov-10-20 08:00AM  
Oct-29-20 12:05PM  
Oct-21-20 08:00AM  
Oct-14-20 08:00AM  
Oct-07-20 08:00AM  
Sep-15-20 08:00AM  
Aug-31-20 06:12PM  
Aug-26-20 06:42AM  
Aug-17-20 08:00AM  
Aug-13-20 08:00AM  
Aug-12-20 03:43PM  
Aug-11-20 04:01PM  
Aug-05-20 11:04AM  
Jul-27-20 05:22AM  
Jul-22-20 08:20AM  
Jul-21-20 08:00AM  
Jul-20-20 08:00AM  
Jun-01-20 05:45AM  
May-29-20 03:08PM  
May-07-20 08:00AM  
May-05-20 08:00AM  
May-04-20 06:45AM  
Apr-30-20 08:00AM  
Apr-29-20 08:00AM  
Apr-21-20 08:00AM  
Apr-20-20 08:00AM  
Apr-16-20 02:00PM  
Apr-15-20 08:00AM  
Apr-09-20 10:30AM  
Apr-01-20 12:00PM  
Mar-18-20 08:00AM  
Mar-02-20 08:00AM  
Feb-18-20 08:00AM  
Feb-03-20 10:10AM  
Jan-13-20 08:00AM  
Jan-12-20 05:05PM  
Jan-09-20 07:22PM  
Jan-06-20 08:00AM  
Jan-03-20 08:00AM  
Nov-26-19 11:35AM  
Nov-14-19 08:00AM  
Oct-22-19 08:00AM  
Oct-17-19 12:30PM  
Oct-15-19 07:30AM  
Oct-10-19 07:30AM  
Sep-27-19 08:30AM  
Sep-25-19 08:57AM  
Aug-28-19 01:15PM  
Aug-26-19 11:30AM  
Aug-13-19 07:00AM  
Jul-22-19 08:01PM  
Jul-17-19 11:35PM  
Jul-10-19 10:45AM  
Jul-08-19 04:03PM  
Jun-07-19 08:00AM  
May-28-19 08:22AM  
May-23-19 09:45AM  
May-20-19 02:30PM  
Apr-23-19 07:45AM  
Apr-11-19 10:00AM  
Apr-02-19 07:45AM  
Mar-18-19 07:45AM  
Mar-15-19 07:45AM  
Mar-12-19 07:45AM  
Feb-20-19 07:45AM  
Jan-21-19 11:52AM  
Dec-19-18 08:00AM  
Dec-12-18 08:00AM  
Dec-04-18 09:45AM  
Nov-01-18 07:30AM  
Oct-16-18 07:30AM  
AzurRx BioPharma, Inc., a clinical stage biopharmaceutical company, focuses on the development of recombinant proteins for the treatment of gastrointestinal diseases. Its therapeutic products administer patients as oral non-systemic biologics. The company's lead therapeutic is MS1819, a recombinant lipase for the treatment of exocrine pancreatic insufficiency (for cystic fibrosis and chronic pancreatitis patients). It is also developing two clinical programs using proprietary formulations of niclosamide, a pro-inflammatory pathway inhibitor, including FW-420, for grade 1 Immune Checkpoint Inhibitor-associated colitis and diarrhea in oncology patients; and FW-1022, for COVID-19 gastrointestinal infections. The company was incorporated in 2014 and is headquartered in Delray Beach, Florida with scientific operations in Langlade, France and clinical operations in Hayward, California.